ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Psychomotor Agitation
Brain Diseases
Neurodegenerative Diseases

Alzheimer's Disease trials near Birmingham, AL, USA:

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU...

Enrolling
Alzheimer's Disease
Alzheimer's Disease, Familial
Drug: lecanemab

Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 5 other locations

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

Birmingham, Alabama, United States and 29 other locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 37 other locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 37 other locations

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Birmingham, Alabama, United States and 117 other locations

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Birmingham, Alabama, United States and 168 other locations

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU-002)

compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD).Stage 2 will evaluate the effect of earl...

Not yet enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Matching Placebo (Remternetug)
Drug: Remternetug

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 34 other locations

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determ...

Not yet enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Matching Placebo (Remternetug)
Drug: Remternetug (SC)

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 34 other locations

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

outpatient study in subjects with psychosis associated with Alzheimer's Disease.The primary objective of the study is to evaluate r ...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: Placebo
Drug: KarXT

Phase 3

Karuna Therapeutics
Karuna Therapeutics

Homewood, Alabama, United States and 106 other locations

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Birmingham, Alabama, United States and 122 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems